A. Menarini Industrie Farmaceutiche Riunite Srl - Company Profile
Powered by 
All the data and insights you need on A. Menarini Industrie Farmaceutiche Riunite Srl in one report.
$295
- Save hours of research time and resources with
our up-to-date A. Menarini Industrie Farmaceutiche Riunite Srl Strategy Report
- Understand A. Menarini Industrie Farmaceutiche Riunite Srl position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
A. Menarini Industrie Farmaceutiche Riunite Srl (Menarini) carries out research, development and manufacturing of pharmaceuticals in various therapeutic areas. The company conducts its operations under three divisions, namely, therapeutic and wellness areas, biotechnology and diagnostics. Menarini's therapeutic and wellness areas division offers various OTC products, prescription drugs, and medical devices.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D focuses to develop the innovation in life sciences to improve the health of patients. The company’s R&D concentrates on two therapeutic areas such as oncology and infectious diseases. Its activities are working on developing therapeutic medicines related such as Breast cancer, Chronic myelomonocytic leukemia, Myelofibrosis, Glioblastoma, Colorectal cancer, Solid tumors and Blastic plasmacytoid dendritic cell neoplasm, which are in Phase I, II and III. The company has nine research centers across Europe, the US and Southeast Asia.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer